BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InfraReDx, Royal Philips Electronics N.V. (PHG) Will Collaborate on Cardiovascular Imaging Systems


10/16/2012 6:48:00 AM

BURLINGTON and ANDOVER, Mass. – October 16, 2012 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) today announced they have signed a joint development and collaboration agreement that is focused on integrating Infraredx’s true vessel characterization (TVC) Imaging System with Philips’ Allura Xper catheterization (cath) lab imaging systems. This collaboration is intended to enable seamless access to the TVC Imaging System with Philips’ Allura X-ray systems.

“Philips is the premier provider of X-ray imaging technology for interventional cardiologists and we are pleased to partner with them on developing this integrated solution,” said Don Southard, president and chief executive officer of Infraredx. “Our goal is to offer physicians easier access to the TVC Imaging System’s near-infrared spectroscopy and intravascular ultrasound technology for use in determining the true extent of cardiovascular disease, especially the presence of lipid core plaques (LCPs). The TVC Imaging System is experiencing accelerated adoption in the U.S. and Europe. We believe this growth is the result of mounting clinical evidence around the role of LCP and continuous system enhancements.”

The joint product development is intended to provide physicians with tableside control of the TVC Imaging System from within the sterile cath lab environment using Allura’s table-mounted Xper module. The TVC Composite Image can be viewed on the Philips’ cath lab monitors, enabling physicians to view the Chemogram and intravascular ultrasound (IVUS) images alongside the coronary angiogram. This will allow for better visualization of LCPs in a patient’s coronary artery. The automatic sharing and integration of patient demographics and imaging study information between the Allura system and the TVC system will improve workflow efficiency and provide quicker retrieval and review of information.

“As the global market leader in cath lab imaging technology, we strive to offer advanced clinical applications that enable interventional procedures to be performed more effectively,” said Bert van Meurs, senior vice president and general manager, Interventional X-ray, Philips Healthcare. “The collaboration with Infraredx supports our commitment to continuously improve the integrated functioning of our cath labs and further enhance the user experience.”

About The TVC Imaging System™

The TVC Imaging System™ is a first-in-class intravascular imaging system that holds the potential to revolutionize the management of coronary artery disease by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The TVC Imaging System helps interventional cardiologists identify which patients are prone to complications during stenting. The device enables cardiologists to predict peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid core plaques (LCP) of interest.

In a single pullback, the TVC Imaging System provides rapid and automated detection of LCPs during the cardiac catheterization procedure. The device is the only multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through IVUS technology, the TVC Imaging System provides clear and relevant information about vessel structure, in real time. The system’s enhanced IVUS image provides a clear view of the vessel and plaque, providing more reliable vessel interpretation and assessment. The system’s NIRS technology enables interventional cardiologists to reliably visualize the presence of LCP and predict the risk of peri-stenting myocardial infarction. The multimodality images are obtained simultaneously and require no post-processing or image manipulation. The TVC Imaging System is the only device available in both the U.S. and Europe for the detection of LCPs. Outside of the U.S., the TVC Imaging System is available in more than 30 countries worldwide.

About Infraredx, Inc.

Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Through the use of both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technologies, the system helps interventional cardiologists identify which patients are prone to stenting complications by assessing not only the degree of stenosis, but also the presence of lipid core plaque. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com.

About Royal Philips Electronics

Royal Philips Electronics (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2011 sales of EUR 22.6 billion and employs approximately 122,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming, home and portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Contacts:

Infraredx, Inc.

Grant Frazier, 781-345-9632

Vice President of Marketing

gfrazier@infraredx.com

or

Philips

Rachel Bloom-Baglin, 978-659-3748

Senior Director, Communications

Rachel.bloom-baglin@philips.com

or

Philips

Steve Klink, +31 6 10888824

Senior Press Officer

steve.klink@philips.com

or

Pure Communications, Inc.

Susan Heins (media), 864-286-9597

sjheins@purecommunicationsinc.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES